News | August 16, 2021
Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company reports revenue growth of 26% and PAT growth of 21% YoY
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
Investment of Rs 235 crores to add 411 beds in the next 18 months
The hospital chain aggressively embarks on digitisation and is e-health ready
National Accreditation Board for Hospitals & Healthcare Providers (NABH) is a constituent board of the Quality Council of India, set up to establish and operate accreditation programmes for healthcare organisations
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Subscribe To Our Newsletter & Stay Updated
